Autoantibodies in Psoriatic Disease

Abstract

Background Psoriasis (Ps) is an inflammatory skin disease affecting over 8 million people in the USA and Canada. Approximately a quarter of patients with Ps have an inflammatory arthritis termed psoriatic arthritis (PsA). Psoriatic disease encompassing both Ps and PsA is regarded as an immune-mediated inflammatory disease, exhibiting both autoimmune and autoinflammatory features. Innate immune cell activation promotes inflammation and the cellular infiltrate in inflamed tissue is predominantly lymphocytic. Content A narrative review of the current literature on the presence and clinical significance of autoantibodies found in psoriatic disease are presented. The frequency of several autoantibodies in Ps and PsA patients as well as their association with disease diagnosis, disease activity, and treatment response are reviewed. Summary Despite historically described as a rheumatoid factor negative (seronegative) disease, an array of autoantibodies has been identified in patients with psoriatic disease. Many of the autoantibodies reviewed are elevated in Ps and PsA patients and are associated with disease activity, treatment response, and cardiovascular disease risk. The identification of autoantibodies in Ps and PsA patients points to an autoimmune component potentially playing a role in psoriatic disease; however, additional evidence is needed to determine the clinical utility of these autoantibodies and their contribution to disease pathogenesis.

Deciphering the therapeutic potential of trimetazidine in rheumatoid arthritis via targeting mi-RNA128a, TLR4 signaling pathway, and adenosine-induced FADD-microvesicular shedding: In vivo and in silico study

“…Our results revealed a considerable increase in serum anti-dsDNA, anti-CarP, anti-MCV, and ANA levels in the FCA-induced RA model. Previous research has presented compelling evidence that indicates that individuals diagnosed with RA often exhibit the presence of autoantibodies, including but not limited to anti-dsDNA, anti-CarP, anti-MCV, and ANA ( Willemze, 2012 ; Willemze et al, 2012 ; Koussiouris and Chandran, 2022 ). In our study, TMZ treatment demonstrated a notable reduction in serum levels of these antibodies, which was comparable to the effect observed with MTX.…”